Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | HAT1 | O14929 | 4/20 | 1.00 |
| ▸ | RBBP7 | Q16576 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TST | Q16762 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin SCHEMBL29374783 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL5899262 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL29456492 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL2420598 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL7706 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL13373926 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL9609755 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL14146654 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL7707 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL12979917 | 1.00 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676451-A1 | COMPOSITION COMPRISING MEDIUM-CHAIN TRIGLYCERIDES, OMEGA-3 AND CHOLINE FOR USE IN A METHOD OF TREATMENT OF COGNITIVE DECLINE AND DEMENTIA | Global Pharmacies Partner S.R.L. in Forma Abbreviata G.P.P. S.R.L. (IT) | 2026-01-14 | — | — | EP | claimed |
| US-20240377326-A1 | USE OF FLUORESCENT OR VISIBLE TRACERS TO MONITOR NUTRIENT CONCENTRATIONS IN SOLUTION | FEHR SOLUTIONS, LLC | 2024-11-14 | — | — | US | claimed |
| WO-2024184869-A1 | COMPOSITION COMPRISING MEDIUM-CHAIN TRIGLYCERIDES, OMEGA-3 AND CHOLINE FOR USE IN A METHOD OF TREATMENT OF COGNITIVE DECLINE AND DEMENTIA | GLOBAL PHARMACIES PARTNER S.R.L. IN FORMA ABBREVIATA G.P.P. S.R.L. (IT) | 2024-09-12 | — | — | WO | claimed |
| WO-2022109347-A9 | METHODS FOR PACKAGING MATERIALS, BOXES, AND CONTAINERS USING PHOTOSENSITIZERS FOR PATHOGEN REDUCTION | Mi2 Holdings LLC (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2023043974-A1 | USE OF FLUORESCENT TRACERS TO MONITOR NUTRIENT CONCENTRATIONS IN SOLUTION | FEHR SOLUTIONS, LLC (US) | 2023-03-23 | — | — | WO | claimed |
| WO-2022109347-A1 | METHODS FOR PACKAGING MATERIALS, BOXES, AND CONTAINERS USING PHOTOSENSITIZERS FOR PATHOGEN REDUCTION | Mi2 Holdings LLC (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220154404-A1 | Active Materials, Surfaces, Surface Treatments And Methods For Packaging Materials, Boxes, And Containers Using Photosensitizers For Pathogen Reduction | Mi2 Holdings LLC (US) | 2022-05-19 | — | — | US | claimed |
| US-20220031887-A1 | Active Materials, Surfaces, Surface Treatments And Methods Using Inclusion Complex Formers For Pathogen Reduction | Mi2 Holdings LLC (US) | 2022-02-03 | — | — | US | claimed |
| WO-2021231634-A1 | ACTIVE MATERIALS, SURFACES, SURFACE TREATMENTS AND METHODS USING INCLUSION COMPLEX FORMERS FOR PATHOGEN REDUCTION | Mi2 Holdings LLC (US) | 2021-11-18 | — | — | WO | claimed |
| EP-3710108-A1 | MODULATION OF BIOPHOTONIC REGIMENS | Klox Technologies Limited (IE) | 2020-09-23 | — | — | EP | claimed |
| EP-2986136-B1 | COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING | MARS INC (US) | 2020-08-12 | — | — | EP | claimed |
| US-10548935-B2 | Composition and method for preventing, reducing, alleviating or treating idiopathic vomiting | MARS, INCORPORATED (US) | 2020-02-04 | — | — | US | claimed |
| EP-2986136-A1 | COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING | The Iams Company (US) | 2016-02-24 | — | — | EP | claimed |
| CN-105188400-A | Compositions and methods for preventing, reducing, alleviating, or treating idiopathic vomiting | IAMS COMPANY | 2015-12-23 | — | — | CN | claimed |
| US-20140271949-A1 | Composition and Method for Preventing, Reducing, Alleviating or Treating Idiopathic Vomiting | THE IAMS COMPANY (US) | 2014-09-18 | — | — | US | claimed |
| WO-2014143539-A1 | COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING | THE IAMS COMPANY (US) | 2014-09-18 | — | — | WO | claimed |
| EP-1708882-A1 | METHOD OF TRACING PROCESS PRINTING FLUIDS | Nalco Company (US) | 2006-10-11 | — | — | EP | claimed |
| US-20060150850-A1 | Method of tracing process printing fluids | ECOLAB USA INC. | 2006-07-13 | — | — | US | claimed |
| WO-2005072964-A1 | METHOD OF TRACING PROCESS PRINTING FLUIDS | NALCO COMPANY (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050166780-A1 | Method of tracing process printing fluids | NALCO COMPANY | 2005-08-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031887-A1 | Active Materials, Surfaces, Surface Treatments And Methods Using Inclusion Complex Formers For Pathogen Reduction | PPOX, CYBA, FMNL1 | MEN1 1287/4885KMT2A 4012/4885USP2 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.